Clinical trial
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer…
NCT00098605 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00098605 |
|---|---|
| Title | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases |
| Official title | A Phase 2 Study of GW572016 for Brain Metastases in Patients With HER2-Positive Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain |
| Intervention type | Drug, Other, Procedure |
| Interventions | lapatinib ditosylate, laboratory biomarker analysis, quality-of-life assessment, questionnaire administration |
| Enrollment | 37 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2006 |
| First posted | Dec 8, 2004 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: